Table 1.
Characteristics of Randomized Controlled Trials Comparing Denosumab With Bisphosphonates for Osteoporosis Treatment
| Included Trials (Location) | Treatment Status | Basic Therapy a | Bisphosphonate Type | Denosumab Group (60 mg⁄6 mo) | Bisphosphonate Group | Duration (Mo) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Age (SD), y | BMD TH (SD) b | BMD LS (SD) b | No. | Age (SD), y | BMD TH (SD) b | BMD LS (SD) b | Dosage | |||||
| McClung (9) (United States) | Untreated | Ca 1000 mg; Vit D 400 IU | Alendronate | 47 | 63.1 (8.1) | −1.4 (0.8) | −2.2 (0.7) | 47 | 62.8 (8.2) | −2.0 (0.9) | −2.0 (0.9) | 70 mg once weekly for 12 mo | 12 |
| Kendler (26) (international) | Bisphosphonate treated | Ca 1000 mg; Vit D 400 IU | Alendronate | 253 | 66.9 (7.8) | −1.8 (0.82) | −2.6 (0.75) | 251 | 68.2 (7.7) | −1.8 (0.7) | −2.6 (0.8) | 70 mg once weekly for 12 mo | 12 |
| Brown (25) (international) | Untreated | Ca 500 mg; Vit D 400 or 800 IU | Alendronate | 594 | 64.1 (8.6) | −1.8 (0.8) | −2.6 (0.8) | 595 | 64.6 (8.3) | −1.7 (0.8) | −2.6 (0.8) | 70 mg once weekly for 12 mo | 12 |
| Recknor (27) (international) | Bisphosphonate treated | Ca ≥500 mg; Vit D 800 IU | Ibandronate | 417 | 67.2 (8.1) | −1.8 (0.7) | −2.5 (0.9) | 416 | 66.2 (7.8) | −1.8 (0.7) | −2.5 (0.8) | 150 mg once monthly for 12 mo | 12 |
| Nakamura (28) (Japan)c | Previous fractures | Ca ≥600 mg; Vit D 400 IU | Alendronate | 472 | 69.9 (7.4) | −2.0 (0.8) | −2.8 (0.9) | 242 | 70.2 (7.3) | −2.0 (0.8) | −2.7 (0.9) | 35 mg once weekly for 24 mo | 24 |
| Roux (29) (international) | Bisphosphonate treated | Ca ≥1000 mg; Vit D 800 IU | Risedronate | 435 | 67.8 (7.0) | −1.6 (0.9) | −2.2 (1.2) | 435 | 67.7 (6.8) | −1.9 (0.7) | −2.3 (1.1) | 150 mg once monthly for 12 mo | 12 |
| Anastasilakis (30) (Greece)d | Bisphosphonate treated | Ca 1000 mg; Vit D 800 IU | Zoledronic acid | 34 | 63.2 (9.6) | — | −1.9 (1.3) | 30 | 63.3 (10.1) | — | −2.18 (0.9) | 5-mg Infusion once yearly for 12 mo | 12 |
| Miller (31) (international) | Bisphosphonate treated | Ca ≥1000 mg; Vit D ≥800 IU | Zoledronic acid | 321 | 68.5 (7.1) | −1.9 (0.7) | −2.7 (0.8) | 322 | 69.5 (7.7) | −1.9 (0.8) | −2.6 (0.9) | 5-mg Infusion once yearly for 12 mo | 12 |
| Kendler (32) (international) | Untreated | Ca 1000 mg; Vit D ≥400 IU | Alendronate | 126 | 65.1 (7.6) | −1.60 (0.74) | −2.04 (1.16) | 124 | 65.3 (7.7) | −1.60 (0.76) | −1.89 (1.13) | 70 mg once weekly for 12 mo | 12 |
| Niimi (33) (Japan)e | Teriparatide treated | Active or native Vit D in DMAb arm | Alendronate | 100 | 78.0 (8.0) | — | −1.7 (1.6) | 100 | 78.0 (9.0) | — | −1.7 (1.2) | 35 mg once weekly for 12 mo | 12 |
Abbreviations: —, no data; Ca, calcium; DMAb, denosumab; LS, lumbar spine; TH, total hip; Vit D, vitamin D.
a
The doses in basic therapy were given daily.
b
T-scores were used.
c
Included 95% women and 5% men; we used the data of the whole population.
d
Age and BMD were calculated based on patients who completed the study.
e
Included 90% women and 10% men; we used the data of the whole population.